Short answer:
Yes – the effectiveness (or “potency”) of the MMR vaccine can be reduced when you’re on Cosentyx (secukinumab). Because Cosentyx is an IL‑17A blocker, it dampens certain parts of the immune system and the FDA, ACIP and most specialty societies recommend that live‑attenuated vaccines—like MMR—be given before you start therapy (or at least a few weeks after you stop it).
Below is a quick rundown of what you need to know.
| Topic | What you need to know |
|-------|-----------------------|
| Why the MMR might be less effective | Secukinumab blocks IL‑17A, a cytokine important for neutrophil recruitment and defense against viral infections. While it’s not as broad an immunosuppressant as a corticosteroid or anti‑TNF agent, it can still blunt the immune response to a live vaccine, lowering the antibody titer and protective effect. |
| Current guidelines | • The American Academy of Dermatology (AAD), the American College of Rheumatology (ACR), and the American Academy of Pediatrics (AAP) all advise that live vaccines should be administered before starting biologic therapy.
• The general rule of thumb: give the vaccine ≥ 4 weeks (some experts say 2–4 weeks) before therapy, or give it > 6 months after stopping.
• If you’re already on Cosentyx and haven’t been vaccinated, you’re not advised to get the MMR right now because the drug can diminish the vaccine’s effectiveness and potentially increase the risk of adverse events. |
| Practical steps | 1. Check your vaccination status – If you’re unsure, a quick review of your medical records or a CBC/serology screen can confirm if you’re up‑to‑date.
2. Plan ahead – If you’re about to start Cosentyx, schedule a routine MMR (or MMR‑plus if needed) at least 4 weeks before the first dose.
3. If you’re already on Cosentyx – Talk to your treating provider. They may decide to wait until you finish the drug or pause the medication temporarily to give you the vaccine, but that depends on disease activity and the urgency of the vaccination. |
| What happens if you miss it? | • If you’re on Cosentyx and you’ve already received MMR, you’re likely still protected, but the antibody level might be lower than in someone not on immunosuppression.
• If you need a booster and you’re still on the drug, the response will be less robust. In that case, your doctor may recommend a higher vaccine dose, a second dose, or an alternative vaccine (e.g., an inactivated vaccine for measles—though none is currently available). |
| Side‑effects and safety | MMR is a live‑attenuated vaccine; under immunosuppression, there is a theoretical risk of vaccine‑derived infection. That’s why it’s contraindicated during active biologic therapy. |
| Key take‑away | Always vaccinate before starting Cosentyx. If you’re already on the drug, check with your dermatologist/rheumatologist before getting MMR. |
How to talk to your provider
- Ask about your immunization history – Bring a list of vaccines you’ve received.
- Explain you’re planning to start Cosentyx – Emphasize the importance of catching up on live vaccines first.
- Ask about a vaccination schedule – Many clinicians will give the MMR 2–4 weeks before the first dose of secukinumab.
- If you’re already on Cosentyx – Request a review of the benefits of vaccinating now vs. waiting until you stop the drug.
- Follow up – After the vaccine, you can have your provider check for serologic response if you’re still concerned.
---
Bottom line
- Cosentyx can reduce the immune response to MMR.
- Live vaccines should be given before you start therapy.
- If you’re already on Cosentyx, discuss timing and safety with your provider.
Stay safe and up‑to‑date—vaccinations are a key part of protecting yourself while on immunomodulatory therapy!